

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols has approved an operational improvement plan designed to reinforce its competitiveness and build a more streamlined, efficient and cost-effective global organization. Under this new initiative, Grifols will significantly reduce its cost base, improve operational cash flow, drive financial performance, and create a more agile and effective operating model.

The plan focuses on three major areas: optimizing plasma costs and operations, streamlining corporate functions, and enhancing other efficiencies across the organization. Grifols expects to achieve annualized cost savings of approximately EUR 400 million relative to comparable 2022 full year costs. While measures comprising most or all of these savings are expected to be implemented by the fourth quarter of 2023, due to the company's inventory accounting as well as timing of implementation, it is expected that approximately EUR 100 million of savings will be recognized for income statement purposes in 2023. Most of the annualized cost savings will be recognized for income statement purposes in 2024.

This plan will be initiated in the first quarter of 2023 and is expected to be completed through the fiscal year, subject to applicable law and consultation requirements.

The first part of the plan, **optimization of plasma costs and operations**, was designed with the objective of creating a more efficient, contemporary, high quality, and donor-friendly plasma procurement operation. The plan aims to maintain desired plasma volumes while reducing the cash cost per liter of plasma through a set of measures expected to generate annualized savings of at least up to EUR 300 million relative to full year 2022.

These measures will also reduce the U.S. plasma operations workforce by approximately 2,000 positions in 2023.

The second part of the plan is focused on **streamlining corporate functions** covering a broad range of initiatives such as centralizing and automating functions, more fully sharing services across business units, consolidating vendors, streamlining reporting structures, and eliminating duplicative functions and positions, among others. These initiatives will impact close to 300 FTEs, most of whom are in the U.S., with approximately one-third located in Spain.

The third part of the plan, **enhancing other efficiencies across the organization**, will enable the company to reduce operational costs related to, among other things, global procurement, logistics, and facilities, in part due to a real estate rationalization affecting certain offices but not industrial facilities.

Grifols estimates a one-time charge of approximately EUR 140 million to deliver the cost savings initiatives. The charge will be recognized in the first quarter of fiscal 2023 and is derived mainly from severance payments, advisory fees, and other restructuring activities.

GRIFOLS

Further detail on both the cost savings initiative and Grifols' growth strategy will be provided at the publication of the company's Q4 2022 & Full Year Results on February 28, 2023.

In Barcelona, on February 15, 2023

Nuria Martín Barnés
Secretary to the Board of Directors